Stockscreener 앱 받기
3.3001
3.79%
-0.1299
전일 마감가:
$3.43
열려 있는:
$3.44
하루 거래량:
19,133
Relative Volume:
0.34
시가총액:
$2.39M
수익:
-
순이익/손실:
$-14.93M
주가수익비율:
-0.0124
EPS:
-266.137
순현금흐름:
$-15.87M
1주 성능:
-9.34%
1개월 성능:
-60.95%
6개월 성능:
-88.89%
1년 성능:
-97.97%
1일 변동 폭
$3.30
$3.48
1주일 범위
$3.30
$4.02
52주 변동 폭
$3.21
$236.94
트랜스코드 테라 Stock (RNAZ) Company Profile
명칭
Transcode Therapeutics Inc
전화
857-301-6857
주소
6 LIBERTY SQUARE, BOSTON
RNAZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
3.39 | 2.39M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.27 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
708.22 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
662.34 | 39.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.15 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
121.55 | 29.15B | 3.30B | -501.07M | 1.03B | -2.1146 |
트랜스코드 테라 주식(RNAZ)의 최신 뉴스
TransCode Therapeutics Secures Nasdaq Listing Status After Meeting Critical Requirements - StockTitan
SABBY MANAGEMENT, LLC Acquires Shares in TransCode Therapeutics Inc - GuruFocus.com
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update - Defense World
Financial Analysis: TransCode Therapeutics (NASDAQ:RNAZ) & Eliem Therapeutics (NASDAQ:ELYM) - Defense World
HC Wainwright Has Optimistic Outlook of RNAZ FY2024 Earnings - Defense World
Analysts Issue Forecasts for RNAZ Q1 Earnings - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
H.C. Wainwright raises TransCode Therapeutics target following SRC go-ahead for Cohort 3 - Investing.com
Clinical Trials News Live Feed - StockTitan
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial - StreetInsider.com
TransCode advances to third patient group in cancer trial - Investing.com India
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Transcode announces SRC approved third cohort in TTX-MC138 clinical trial - TipRanks
RNAZTransCode Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Transcode Therapeutics stock hits 52-week low at $6.89 By Investing.com - Investing.com Canada
TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4 - MSN
Janux, Vir stocks rally on positive data for Janux drug JANX007 - MSN
TransCode Therapeutics Raises $8M in Private Placement - TipRanks
Why TransCode Therapeutics (RNAZ) Stock Is Diving - Benzinga
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split - The Manila Times
TransCode Therapeutics Announces Reverse Stock Split - TipRanks
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Meet Nasdaq Requirements | RNAZ Stock News - StockTitan
TransCode Therapeutics announces $8M private offering - MSN
Transcode Therapeutics issues 21.2M shares at 37.7c in private placement - Yahoo Finance
TransCode secures $8 million in private placement - Investing.com India
TransCode secures $8 million in private placement By Investing.com - Investing.com Australia
TransCode Therapeutics, Inc. Announces $8 Million Private Placement - The Manila Times
TransCode Therapeutics Secures $8M Private Placement, Issues 21.2M Shares | RNAZ Stock News - StockTitan
TransCode Therapeutics, Inc. announced that it expects to receive $8 million in funding - Marketscreener.com
Transcode Therapeutics announces 1-for-33 reverse stock split - Yahoo Finance
TransCode Therapeutics approves reverse stock split By Investing.com - Investing.com South Africa
TransCode Therapeutics advances with stockholder approvals By Investing.com - Investing.com Canada
TransCode Therapeutics advances with stockholder approvals - Investing.com
TransCode Therapeutics approves reverse stock split - Investing.com
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Maintain Nasdaq Listing | RNAZ Stock News - StockTitan
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results - Yahoo Finance
Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell? - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Defense World
Craig Hallum Downgrades Sow Good (NASDAQ:SOWG) to Hold - Defense World
The Goldman Sachs Group Boosts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $41.00 - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World
Sow Good (NASDAQ:SOWG) Lowered to Neutral Rating by Roth Mkm - Defense World
Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
TransCode Therapeutics Inc (RNAZ) Quarterly 10-Q Report - Quartz
Transcode Therapeutics Reports Increased Losses Amid Funding Challenges - TipRanks
트랜스코드 테라 (RNAZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.32%
0.45%
자본화:
|
볼륨(24시간):